報價延遲最少15分鐘:2025/05/10 14:26 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.15 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.26/-3.82
|
|
企業價值
5.27M
|
| 資產負債 |
|
每股賬面淨值
3.01
|
| 現金流量 |
|
現金流量率
0.05
|
| 損益表 |
|
收益
12.74M
|
|
每股收益
7.87
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/05/10 14:26 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries. |